Columbia University

Technology Ventures


CalCardia: Heart failure is a progressive disorder of weakening heart muscle and increased risk of fatal arrhythmias that affects 5 million Americans. Abnormal calcium overload within heart muscle cells plays a key role in the development and progression of this disorder. Currently available therapies only indirectly improve calcium handling and have limited efficacy. We have recently made a series of seminal discoveries identifying critical protein interactions that regulate calcium levels in heart muscle cells. Using a comprehensive screening program, we have identified four compounds that regulate these pathways and are testing them as novel therapies for the treatment of heart failure. These compounds may also be useful for treating other conditions caused by abnormal calcium handling such as CPVT (catecholaminergic polymorphic ventricular tachycardia), a rare inherited disorder characterized by fatal arrhythmias during strenuous activity in young individuals. This provides a unique opportunity to pursue orphan drug status in order to qualify for specialized FDA funding and fast-track drug approval. We are currently seeking funds to expand our screening and pre-clinical testing program.

To learn more about this opportunity, contact:

Joan José Martínez
Technology Licensing Officer